CD163 and non-small cell lung carcinoma: CD3+ (HR = 0.586, 95% CI 0.275–1.246, P = 0.152, Supplementary Fig. 3A), CD4+ (HR = 0.687, 95% CI 0.327–1.442, P = 0.325, Supplementary Fig. 3B), CD8+ (HR = 1.095, 95% CI 0.521–2.298, P = 0.810, Supplementary Fig. 3C), CD20+ (HR = 0.762, 95% CI 0.363–1.598, P = 0.472, Supplementary Fig. 3D) lymphocyte infiltration and CD163+ macrophage infiltration (HR = 1.535, 95% CI 0.730–3.226, P = 0.257, Supplementary Fig. 3E), CD163+/CD68+ ratio (HR = 1.661, 95% CI 0.787–3.502, P = 0.202, Supplementary Fig. 3F) had no prognostic significance in patients with NSCLC brain metastases.